Title

Efficacy of optimized multichannel vs conventional tDCS for major depression treatment: A randomized controlled trial

Mohammad Ali Salehinejad*# [1, 2], Marzieh Abdi# [3], Mohsen Dadashi [3*], Amir-Homayun Hallajian [4], Kiomars Sharifi [5], Ali Khadem [6], Ricardo Salvador [7], Giulio Ruffini [7], Michael A. Nitsche [1,8, 90]

[1] Department of Psychology and Neurosciences, Leibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany
[2] School of Cognitive Sciences, Institute for Research in Fundamental Sciences (IPM), Tehran, Iran
[3] Department of Clinical Psychology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
[4] Donders Institute for Brain, Cognition, and Behaviour, Radboud University, Nijmegen, The Netherlands
[5] Department of Information Technology and Electrical Engineering, ETH Zurich, Zurich, Switzerland
[6] Department of Biomedical Engineering, Faculty of Electrical Engineering, K. N. Toosi University of Technology, Tehran, Iran
[7] Neuroelectrics Barcelona, Barcelona, Spain
[8] Bielefeld University, University Hospital OWL, Protestant Hospital of Bethel Foundation, University Clinic of Psychiatry and Psychotherapy
[9] German Center for Mental Health, Bochum, Germany

Main text word (excluding methods): 4229
number of figures: 6
Number of Tables: 1
# These authors share first authorship
* Corresponding authors

Abstract

Introduction: Transcranial direct current stimulation (tDCS) has been proposed for treating depression. While it has advantages such as affordability, home-use application and fewer side effects its clinical efficacy is not yet established. This randomized, sham-controlled trial (NCT06165445) compares efficacy of an optimized multichannel protocol vs conventional and sham tDCS for depression treatment.

Methods and Materials: Sixty patients with major depression received 30 sessions of conventional, optimized multichannel, or sham tDCS in parallel groups. In the multichannel optimized tDCS, electrical current was delivered via 7 small electrodes (1.65 mA max current per electrode, 4.0 mA total injected current per polarity) while in the conventional (2 mA max current per electrode, 2.0 mA total injected current per polarity) and sham tDCS large anodal and cathodal electrodes were used. Intervention efficacy and treatment response were evaluated before treatment and after the 10th, 20th, and 30th sessions, 1- and 3-months post-intervention. Cognitive functions and brain connectivity were also assessed.

Results: Both active tDCS groups showed a significant reduction in depressive symptoms compared to the sham group, with the multichannel protocol demonstrating effects as early as the 10th session and achieving greater symptom alleviation than conventional tDCS. A response rate of 72.7% is observed, based on at least a 50% improvement in depressive scores from baseline at 1 month (Hedge's g=2.80) and 3 months (Hedge's g=2.31) post-treatment. Furthermore, the multichannel protocol improved cognitive functions and enhanced cerebral functional connectivity markers of depression pathophysiology.

Discussion: The optimized multichannel tDCS showed high efficacy for treating depression.

Keywords: major depression; transcranial direct current stimulation; dorsolateral prefrontal cortex; noninvasive brain stimulation; cognition

1- Introduction

Major depression (MD) is the most common mental health disorder, affecting about 350 million people worldwide (Guilbert, 2003). It is the second most frequent disease with the highest age-adjusted disability, according to the latest report about the global burden of disability (Ferrari et al., 2024). Individuals with MD are affected by depressed mood, diminished interests, impaired cognitive function, and disturbed sleep or appetite (Otte et al., 2016). Antidepressants, especially Selective Serotonin Reuptake Inhibitors (SSRIs), and psychotherapeutic interventions, especially cognitive-behavioral therapy, are considered first-line treatments for MD with severe and mild to moderate severity, respectively (Gautam et al., 2017; Kendrick et al., 2019). These treatments, nevertheless, come with some limitations. For example, SSRIs have delayed therapeutic benefits, taking about 4 to 6 weeks to ameliorate symptoms (Taylor et al., 2006). Psychotherapy is mostly beneficial for patients with mild and moderate illness severity, but more than half of MD patients receiving therapy do not respond, and only one-third achieve remission. The latest meta-analysis of psychotherapy outcomes for eight mental disorders indicates that while psychotherapies are effective compared to control conditions, the absolute response rates are modest, suggesting a need for more effective interventions for patients who do not respond to first-line treatments (Cuijpers et al., 2024). Accordingly, researchers and clinicians have been interested in developing other potential therapeutic interventions that do not have such limitations.

No established mechanism can explain all aspects of MD. However, previous neuroimaging studies have shown that MD is associated with functional changes in brain circuits such as the cognitive control network and the affective salience network (Mulders et al., 2015; Otte et al., 2016; Wang et al., 2022). Furthermore, studies that monitored resting state

electroencephalography (EEG) of patients with depression have shown that depression is associated with generally reduced and/or altered neural synchronization patterns (Liu et al., 2024; Wang et al., 2024b) and lower coherence (Huang et al., 2023; Wang et al., 2024b) in the default mode and central executive networks which are related to both cognitive impairment and emotional dysregulation in depression. These alterations in neural networks are linked to negative thinking patterns and cognitive symptoms of depression including abnormal self-referential thinking and mind-wandering (shown as rumination in depression) (Kaiser et al., 2015). Importantly, they provide opportunities for developing novel interventions that aim to more specifically restore impaired functional changes in MD.

Noninvasive brain stimulation techniques provide unique opportunities to not only study brain functions but also to modify core physiological parameters of human behavior and cognition (e.g., neuroplasticity) in both healthy and clinical populations (Fregni and Pascual-Leone, 2007; Polanía et al., 2018). The success of some noninvasive brain stimulation techniques, such as repetitive transcranial magnetic stimulation (rTMS) – approved by the Food and Drug Administration (FDA) for the treatment of MD (Blumberger et al., 2018) – suggests that other techniques with related physiological effects may be considered as a potential intervention for patients with MD. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that uses a weak direct electrical current to modulate brain activity and excitability (Nitsche and Paulus, 2000; Stagg et al., 2018) with a safe profile (Bikson et al., 2016; Salehinejad and Siniatchkin, 2024). The exact mechanisms by which tDCS works are not fully understood, but its primary mechanism of action, which emerges immediately during stimulation involves subthreshold de- or hyperpolarization of neuronal membrane potentials, resulting in excitability-enhancing effects by anodal, and -reducing effects by

cathodal stimulation in conventional protocols (Stagg and Nitsche, 2011; Polania et al., 2021). In neuropsychiatric disorders that are characterized by functional brain abnormalities (i.e., hyper- or hypoactivity of specific brain region/s and network/s), it is possible to modify altered brain functions with tDCS, and affect target behavior or cognition (Begemann et al., 2020; Fregni et al., 2020; Salehinejad et al., 2022a; Alizadehgoradel et al., 2024).

Functional abnormalities of the dorsolateral prefrontal cortex (DLPFC) are well-documented in MD. Specifically, dysbalanced activity between the left and right DLPFC is documented in depression (Grimm et al., 2008a; Grimm et al., 2008b), which has been the rationale for applying the most commonly used tDCS protocol in MD (i.e., anodal left DLPFC, cathodal right DLPFC). In MD, results of tDCS studies have been promising so far (Brunoni et al., 2017; Fregni et al., 2020; Nikolin et al., 2023), and a recent network meta-analysis and an umbrella review of tDCS meta-analyses (Mutz et al., 2019; Razza et al., 2020) further supported its potential for MD treatment. However, an individual participant data (IPD) meta-analysis of nine large RCTs found no difference between active and sham tDCS during the relatively short acute treatment phase but only in the follow-up period (Moffa et al., 2020). Nonetheless, there are also studies with negative results or placebo effects of tDCS (De Smet et al., 2021; Rimmer et al., 2022) that question the efficacy of tDCS for the treatment of MD prompting researchers to focus on optimizing NIBS, including tDCS, interventions. Yet, knowledge about optimal stimulation parameters and the efficacy of interventions is still limited.

The most commonly used tDCS protocol in MD includes applying two relatively large sponge electrodes (e.g., 35 or 25 cm^2) over the left and right DLPFC, which induces non-focal stimulation of the target regions but also distributes electrical current flow over nearby areas in the brain. It is possible to optimize this protocol using multichannel montages with

computational modeling to improve the specificity and enhance the intensity of the induced

electrical field in the target region (i.e., left and right DLPFC). In this randomized, double-blind,

sham-controlled study, we primarily investigated treatment efficacy of an optimized multi-

channel tDCS protocol targeting the left and right DLPFC (using seven small electrodes,

maximum of 1.65 mA current per electrode, and a total injected current set to 4.0 mA per

polarity), as compared to the conventional bipolar tDCS montage (two 35 cm conventional

electrodes, 2 mA max current per electrode and total injected current) on reducing depressive

symptoms in 60 patients with MD following 30 sessions of tDCS. Additionally, we investigated

treatment response by evaluating symptom changes and monitoring patients over two follow-up

assessments (1 month and 3 months). Finally, we investigated how these interventions affect

cognitive deficit profiles and affect brain functional connectivity in depression. This study is the

first tDCS RCT in MD to examine and compare the impact of a new computationally optimized

multi-channel tDCS intervention on symptom reduction in MD with that of conventional (large

sponges, bipolar) and sham montages.

2. Methods

2.1. Participants

This study had a randomized, double-blind, parallel-group design to prevent blinding

failure and carry-over effects. Sixty individuals diagnosed with MD were recruited from several

neuropsychiatric clinics across the city of Zanjan from 2021-2023. Patients were randomly

assigned to the active multichannel tDCS (N=20), active conventional tDCS (N=20), and sham

tDCS (N=20) groups using the block randomization method (supplementary materials). Sample

size was calculated using power analysis based on a small-to-medium effect size (f=0.20

equivalent to ηp2=0.04, α=0.05, power=0.95, mixed-model ANOVA with 5 measurements, N=57). We added 3 more subjects to the total sample size to compensate for potential dropouts and increase power. The inclusion criteria were: (1) being 18-75 years of age, (2) failure with at least one antidepressant medication, (3) not currently using antidepressants or having a stable treatment regimen for at least 6 weeks before and throughout the experiment, (4) unipolar depression diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), confirmed by psychiatrists using the Mini International Neuropsychiatric Interview (MINI). Patients had to have a score of 17 points or more on the 17-item Hamilton Depression Rating Scale as well as a low risk of suicide (evaluated based on the MINI). All participants were native speakers (Farsi/Azeri) and had normal or corrected-to-normal vision. This registered clinical trial (ClinicalTrials.gov Identifier: NCT06165445) was approved by the Ethics committee of the Zanjan University of Medical Science (Ethics code: IR.ZUMS.REC.1400.059). Participants gave their written informed consent before participation. See Table 1 for basic demographics.

Fig. 1: CONSORT diagram of study inclusion.

2.2. Clinical outcome measures

The primary outcome measures to examine the effects of the intervention on MD symptoms were the change in depressive symptoms measured by the Hamilton Depression Rating Scale (HDRS-17) score from baseline (Reynolds and Kobak, 1995) and Montgomery–Åsberg Depression Rating Scale (MADRS) (Montgomery and Åsberg, 1979) score changes versus baseline. The Beck Depression Inventory (BDI-II) (Kühner et al., 2007), a self-report questionnaire in contrast to clinician-administered HDRS and MADRS, was also used as the secondary outcome measure. For a detailed description of these measures see supplementary information.

2.3. Cognitive assessment

A neuropsychological test dedicated to depression from the CANTAB computerized test battery (Sahakian and Owen, 1992) was used to assess cognitive deficits in patients before and after the intervention. The battery includes computerized tasks measuring working memory (Spatial Working Memory-SWM), attention (Rapid Visual Processing- RVP), and executive functions (One Touch Stockings of Cambridge- OTS). A detailed description of these measures is provided in the supplementary information. Briefly, the SWM measures working memory and executive functions. Participants are presented with a series of boxes depicted on a screen. Some boxes contain tokens, and the goal is to find and remember the locations of these tokens (Sweeney et al., 2000). The RVP is a sensitive measure of sustained visual attention (Langley et al., 2023) and presents participants with a white box in the center of the computer screen, inside which digits from 2 to 9 appear in a pseudo-random order at the rate of 100 digits per minute. Participants are asked to detect target sequences of numbers and respond using a press pad. The OTS, a modified version of the Tower of London task, requires participants to rearrange colored balls in vertical columns to match a desired final arrangement in a specified minimum number of moves (Sweeney et al., 2000).

2.4. Brain functional connectivity

2.4.1. EEG Preprocessing and Artifact Removal

EEG signals were recorded with a 21-channel EEG device (Mitsar, Ltd, Russia) with a sampling rate of 250 Hz, and the included electrodes were Fz, Cz, Pz, C3, T3, C4, T4, Fp1, Fp2, F3, F4, F7, F8, P3, P4, T5, T6, O1, O2, A1, A2. The recordings were obtained in the eyes-open condition for three minutes and then in eyes-closed condition for three minutes (six minutes in total). To preprocess and remove artifacts from the EEG data, we used Makoto's preprocessing

pipeline in the EEGLAB toolbox 2022.1 (Delorme and Makeig, 2004) with MATLAB 2022b

(The MathWorks, Natick, MA). The data were first resampled to 512 Hz, high-pass filtered at

1 Hz and re-referenced to an average reference. We used the CleanlineNoise plugin in

EEGLAB for line noise removal. We then applied ASR (Artifact Subspace Reconstruction),

an automated algorithm that eliminates flatline and noisy channels, low-frequency drifts, and

short-time bursts. Any removed channels were interpolated using the spherical interpolation

method. Afterward, we visually inspected all the raw data to detect artifact-related parts. To

remove non-brain artifacts, we applied Adaptive Mixture ICA (AMICA) to the EEG data to

decompose independent components (ICs). We then used the EEGLAB plugin ICLabel to

identify brain ICs (with a 'brain' label probability of more than 0.8) from all types of ICs,

including Brain, Muscle, Eye, Heart, and others. Finally, we extracted a 60-second segment

from the middle part of each preprocessed EEG and exported it to the BRAINSTORM

software (version November 2024) for further analysis (Tadel et al., 2011).

2.4.2. *EEG analysis*

Functional connectivity was assessed using multiple metrics to capture distinct aspects of

neural synchronization. The time series from each EEG channel was segmented into 60-second

epochs and bandpass filtered into seven frequency bands (delta: 1–4 Hz, theta: 4–8 Hz, alpha 1:

8–10 Hz, alpha 2: 11–13 Hz, beta 1: 13–21 Hz, beta 2: 19–30 Hz, gamma: 30–40 Hz) with finite

impulse response filters. The Hilbert transform was then applied to each filtered signal to extract

its instantaneous phase. For each pair of EEG channels, we quantified connectivity using three

complementary methods: First, we calculated the Phase-Locking Value (PLV) (Lachaux et al.,

1999) which is sensitive to the synchronization of oscillatory neural activity and reflects dynamic

coordination across brain networks. In addition, we computed the Magnitude-Squared Coherence (Nunez et al., 1997), capturing both phase and amplitude relationships by correlating the power spectra of two signals. Lastly, we analyzed global efficiency, a measure of functional connectivity associated with information flow and cognitive performance, using the Weighted Phase Lag Index (wPLI) (Vinck et al., 2011). These connectivity measures were chosen as previous studies have shown that depression is generally associated with reduced and/or altered synchronization patterns (Liu et al., 2024; Wang et al., 2024b) and lower coherence (Huang et al., 2023; Wang et al., 2024b) in the default mode network (DMN) and central executive network (CEN). Further details about these measures, EEG data preprocessing, and analysis are provided in the supplementary information.

2.5. tDCS

In conventional tDCS, direct currents were generated by an electrical stimulator (Oasis Pro, Mind Alive, Canada) and applied through a pair of saline-soaked sponge electrodes (7×5 cm) for 30 minutes (with 30 s ramping up and down) and with an intensity of 2 mA. In sham tDCS, the electrical current was ramped up and down for 30 seconds and then turned off (Brunoni et al., 2014). In the multichannel optimized protocols, stimulation was delivered with the StarStim 8 stimulator (Neuroelectrics, Spain) using 7 small electrodes whose positions and currents were determined with the Stimweaver algorithm (Ruffini et al., 2014). This algorithm determines the protocol (currents and electrode positions) that minimizes the weighted difference between the distribution of the normal component of the E-field in the cortical surface (En), to a target En-map. In this particular case, the target En-map was designed to stimulate the left and right DLPFC with desired excitatory and inhibitory effects, respectively. This was achieved by

setting the target En as positive (directed into the cortical surface) on the left DLPFC region

(here defined as BA46), which leads to an excitatory effect on long pyramidal cells, thus

increasing excitability (Ruffini et al., 2014; Galan-Gadea et al., 2023). The opposite was done for

the right DLPFC target. The Stimweaver algorithm was run on a template biophysical head

model (Miranda et al., 2013), and the current was constrained to a maximum of 2.0 mA per

electrode (in absolute value) and 4.0 mA total injected current (here defined as the sum of the

currents in all the anodes). Stimulation was delivered on 5 consecutive days for six weeks. In the

conventional and sham conditions, anodal and cathodal electrodes were placed over the left

DLPFC (F3), and right DLPFC (F4) respectively using the EEG 10–20 system for electrode

positioning. In the multichannel stimulation condition, F3, AF3, and FC6 were stimulated with

anodal stimulation, and F4, AF4, F8, and FC5 were stimulated with cathodal stimulation. The

distribution of the component of the E-field normal to the cortical surface induced by the

multichannel montage is shown in Figure 2. This specific configuration of electrodes was

expected to result in larger electric fields and more effective modulation of the target regions

according to the modeling of different electrode configurations with different intensities and

electrode placements. tDCS was applied by independent investigators who were not involved in

outcome measure ratings (Gandiga et al., 2006). A side-effect survey was done after each tDCS

session (Brunoni et al., 2011). Blinding efficacy (asking participants to guess about the type of

stimulation) was not explored among patients due to the multi-session design of the study. This

aimed to prevent participants' bias from habituation to tDCS-induced sensations over multiple

sessions. The patients in the sham group were later assigned to active tDCS intervention.

Figure 2: Distribution of the normal component of the E-field (En, in V/m) in a surface inside the grey matter tissue, in between the grey matter-CSF and white matter-grey matter interfaces. Panel **a** shows the En-distribution for a conventional protocol using a bipolar electrode montage with rectangular 7x5 cm^2 sponge electrodes (anode/cathode over F3/F4) at +2/-2-mA . Panel **b** illustrates the En-distribution for a multichannel optimized protocol using gelled electrodes (1 cm radius PiStim electrodes, anodes shown in red, cathodes in blue) targeting Brodmann area 46, presumed to result in excitability enhancement in the left hemisphere and excitability reduction in the right. Positive En values indicate that the En-field is directed into the cortical surface, thus leading to an increase in cortical excitability, according to the lambda-E model. Negative En values are directed in the opposite direction, thus leading to a decrease of excitability.

2.6. Procedure

Prior to the experiment, participants completed a brief questionnaire to evaluate their suitability for brain stimulation. All participants received 30 sessions of stimulation over 5 consecutive weeks (1 session daily from Saturday to Friday, 5 days per week). To avoid confounding effects of the intervention at a circadian non-preferred time of day, which can significantly affect neuroplasticity induction (Salehinejad et al., 2021), all stimulation sessions took place between 11:00-14:00 and participants were not under sleep pressure (Salehinejad et al., 2022b). Clinical outcome measures (BDI-II, HDRS, MADRAS) were evaluated before the first intervention (pre-intervention-T0), after the 10th session (T1), after the 20th session (T2), after the last session (post-intervention-T3), 1 month (T4) and 3 months (T5) following the last stimulation session. Cognitive functions assessment and EEG recordings took place only before and after the intervention, due to COVID-19 restrictions. Patients were instructed about cognitive

tasks before the beginning of the experiment. None of the patients received any kind of psychotherapy during the study. Participants were blinded to the study hypotheses and stimulation conditions. Independent experimenters from those who applied tDCS evaluated the outcome measures for securing blinding (Figure 3).

Fig. 3: Study procedure. The experiment was conducted in a randomized, double-blind, sham-controlled parallel-group design. Patients were assigned to one of three tDCS groups: 2-mA conventional tDCS [total injected current 2 mA] (n = 20), 2-mA optimized multichannel tDCS [total injected current 4 mA] (n = 20), and sham tDCS (n = 20). All participants underwent 30 daily stimulation sessions. Depressive symptoms were evaluated before the intervention and up to three months afterward. Cognitive performance and cerebral functional connectivity were assessed only before and after the intervention due to the COVID-19 pandemic.

2.7. Statistical analysis

Clinical and behavioral data analyses were conducted with the statistical package SPSS, version 26.0 (IBM, SPSS, Inc., Chicago, IL), and GraphPad Prism 8.2.1 (GraphPad Software, San Diego, California). The normality and homogeneity of data distribution, and variance were confirmed by Shapiro-Wilk and Levene tests, respectively. Between-group differences in demographic variables were explored by Chi-square tests or Fisher's exact test for categorical variables and F-tests for continuous variables. Mixed model ANOVAs were conducted for the dependent variables with "group" (multichannel tDCS, conventional tDCS, sham tDCS) as the between-subject and time (five timepoints for clinical measures: pre-intervention, T1, T2, post-intervention, 1-month follow-up, 3-month follow-up; two timepoints for cognitive/EEG measures) as the within-subject factors. Mauchly's test was used to evaluate the sphericity of the data before performing the respective ANOVAs. In case of violation, degrees of freedom were corrected using Greenhouse-Geisser estimates of sphericity. *Post hoc* analyses were calculated using Tukey's multiple comparisons tests to examine individual mean difference comparisons across groups (active multichannel, active conventional, sham) and time points (pre-intervention, session 10, session 20, session 30, 1-month follow-up, and 3-month follow-up). The critical level of significance was 0.05 for all statistical analyses.

For functional connectivity, first within-group differences in post- versus pre-intervention connectivity were evaluated with non-parametric permutation paired t-tests in Brainstorm (Tadel et al., 2011), set at 8,000 iterations ($p \leq 0.05$), and applying FDR correction, targeting each connection in the connectivity matrices. Next, between-group differences in pre-intervention connectivity values were assessed using non-parametric permutation-independent t-tests with the same parameters. Finally, between-group differences in post-intervention connectivity were

examined using the same approach. All between-group analyses were conducted to identify significant differences in functional connectivity across experimental conditions.

3. Results

3.1. Data overview

Participants tolerated the stimulation well, with no adverse effects reported during or after the intervention (Table S1). However, side effects varied significantly between groups. The multichannel tDCS group reported more itching, tingling, and burning sensations during stimulation, along with increased skin redness, headaches, concentration difficulties, and sleep issues afterward, compared to the sham group. The conventional tDCS group experienced higher levels of visual perception during the intervention and fatigue afterward than the sham group. No significant differences were observed in demographic data or baseline clinical/cognitive outcomes among the groups (Table S2).

3.2. Primary clinical measures: Intervention efficacy and treatment response

The results of the 3 (multichannel tDCS, conventional tDCS, sham tDCS) × 6 (pre, T1, T2, T3, 1-month follow-up, 3-month follow-up) mixed ANOVA revealed significant main effects of time ($F_{2.98}$=37.90, p<0.001, ηp^2=0.39), group (F_2=5.24, p=0.008, ηp^2=0.15) and importantly group×time interaction ($F_{5.96}$=9.34, p<0.001, ηp^2=0.24) for the HDRS scores. Tukey's multiple test comparisons show a significant decrease in HDRS scores at all time points (i.e., session 10, session 20, session 30, 1-month follow-up, and 3-month follow-up) in the multichannel tDCS group as compared to the pre-intervention score. In the conventional tDCS, HDRS scores were significantly reduced only after session 30 when compared to pre-intervention scores. When compared to the sham group, only the optimized multichannel tDCS

group showed a significant reduction of HDRS scores at session 20, session 30, 1-month follow-up, and 3-month follow-up assessment and was significantly larger than the conventional tDCS group at session 30, 1-month follow-up and 3-month follow-up assessment. Baseline (pre-intervention) between-group comparisons (active groups vs sham) showed no significant differences (Fig 4A).

Similarly for MADRS scores, a significant main effect of time ($F_{3.26}=57.34$, $p<0.001$, $\eta p^2=0.50$), group ($F_2=5012$, $p=0.008$, $\eta p^2=0.15$) and also significant group×time interaction ($F_{6.53}=7.51$, $p<0.001$, $\eta p^2=0.21$) were found. The MARDS scores significantly decreased from session 20 until the last assessment in both multichannel and conventional tDCS groups when compared to the pre-intervention score and no significant changes in the sham group. Compared to the sham group, MARDS scores were significantly reduced only in the multichannel tDCS group at sessions 30, 1-month, and 3-month follow-up assessments and at sessions 10, 20, 30, and 1-month follow-up as compared to the conventional tDCS (Fig 4B).

3.3. Secondary clinical measure

The results showed a significant main effect of time ($F_{3.14}=32.15$, $p<0.001$, $\eta p^2=0.36$) and group ($F_2=4.74$, $p=0.012$, $\eta p^2=0.14$) and group×time interaction ($F_{6.29}=6.10$, $p<0.001$, $\eta p^2=0.17$) for the BDI-II scores. Tukey's multiple test comparisons show that the multichannel tDCS significantly reduced BDI-II scores at all time points as compared to the pre-intervention score while the conventional tDCS group significantly reduced BDI-II scores at session 30 and both follow-up measurements (Fig 4C). No significant score reduction was found in the sham group after the intervention. When compared to the sham group, BDI-II scores were significantly decreased in the multichannel tDCS group at sessions 30, 1-month, and 3-month follow-up assessments and in the conventional tDCS group at both follow-up assessments. The BDI-II

scores in the multichannel group were also significantly lower at sessions 10 and 20 as compared

to the conventional tDCS (Fig 4C).

Fig. 4: Depressive symptoms measured by the Hamilton Depression Rating Scale (HDRS) (A), Montgomery–Åsberg Depression Rating Scale (MADRS) (B), and Beck Depression Inventory (BDI-II) (C) before, after, and up to 3 months following up the intervention/ In the left panel, filled symbols indicate significant differences at each time point compared to pre-intervention scores. The red and blue floating symbols represent significant differences between the active stimulation groups (conventional and multichannel tDCS) and sham tDCS at each time point. Asterisks show the difference between the multichannel vs sham tDCS groups at respective time points. The right panel displays a scatter plot of clinical scores for each group across time points. All pairwise comparisons used Tukey's multiple-test method, and error bars indicate the standard error of the mean (s.e.m.). Note: HDRS = Hamilton Depression Rating Scale; MADRS = Montgomery–Åsberg Depression Rating Scale; BDI-II = Beck Depression Inventory-II; tDCS = transcranial direct current stimulation; mo = month.

3.4. Cognitive performance

Working memory, sustained attention, and executive functions were assessed before and after the intervention with the SWM, RVP, and OTS tasks respectively. For working memory, the 3×2 mixed model ANOVA results revealed significant main effects of time ($F=4.85$, $p=0.032$, $\eta p^2=0.080$), group ($F=4.77$, $p=0.012$, $\eta p^2=0.146$), and group×time interaction ($F=4.73$, $p=0.012$, $\eta p^2=0.146$) on the number of solved problems. Tukey's multiple comparisons show that only the optimized multichannel tDCS significantly increased the number of solved problems compared to sham ($p=0.025$) and conventional tDCS ($p=0.025$) and also compared to the pre-intervention measure ($p<0.001$). A significant main effect of time was observed on performance error ($F=14.23$, $p<0.001$, $\eta p^2=0.200$), but effects of group or group×time interactions. Post-hoc comparisons of post-intervention vs pre-intervention error rates show a significant error reduction after optimized multichannel tDCS ($p=0.039$, -22.7%) but not in the conventional (-11.51%) and sham tDCS conditions (-3.69%). For the preparation time to response, only a significant main effect of time was found ($F=5.49$, $p=0.023$, $\eta p^2=0.089$). Tukey's multiple test comparisons of post-intervention vs pre-intervention scores, however,

showed no significant decrease in preparation time after the optimized multichannel (-28.2%),

conventional (-3.98%), and sham tDCS (-14.4%) (Fig 5A).

Fig. 5: Cognitive performance was evaluated before and after 30 sessions of optimized multichannel, conventional, and sham tDCS using the CANTAB neuropsychological test battery for depression, which includes measures of working memory (SWM) (A), sustained attention (RVP) (B), and executive functioning (OTS) (C). Asterisks indicate significant differences for pre- and post-intervention comparisons while floating symbols, depending on the color, denote significant group differences (in this case multichannel tDCS vs sham or conventional tDCS) at each time point. Tukey's multiple-test method was used for all pairwise comparisons, and error bars indicate the standard error of the mean (s.e.m.). Note: SWM = Spatial Working Memory; RVP = Rapid Visual Processing; OTS = One Touch Stocking of Cambridge; tDCS = transcranial direct current stimulation.

For sustained attention, the 3×2 mixed ANOVA revealed significant main effects of group on the number of hits ($F=4.15$, $p=0.021$, $\eta p^2=0.136$) and misses ($F=5.21$, $p=0.010$, $\eta p^2=0.150$), along with a significant group×time interaction effect on misses ($F=3.58$, $p=0.034$, $\eta p^2=0.112$) (Table 3). Following post-hoc comparisons, no significant changes were observed in hits or misses post-intervention compared to pre-intervention scores in either group. The number of hits after the intervention was, however, significantly higher in the multichannel tDCS as compared to the conventional, but not sham tDCS. Moreover, delta scores (post-intervention score minus pre-intervention score) were analyzed using a univariate ANOVA. The results showed a significant main effect of group ($F=3.58$, $p=0.034$, $\eta p^2=0.112$), and Tukey's post hoc comparison indicated that missed trials were significantly lower in the optimized multichannel tDCS group than in the sham tDCS group ($p=0.029$). Regarding performance speed (mean latency), significant main effects of time ($F=5.97$, $p=0.019$, $\eta p^2=0.130$) and group ($F=4.09$, $p=0.024$, $\eta p^2=0.170$) were observed, but no significant group×time interaction was found. Post hoc tests revealed no significant differences in performance speed within or between groups (Fig 5B).

Finally for executive functioning, the results of 3×2 mixed ANOVA revealed a significant main effect of time ($F=7.30$, $p=0.009$, $\eta p^2=0.114$) and a group×time interaction ($F=4.51$, $p=0.016$, $\eta p^2=0.135$) on the number of solved problems. For the number of errors before the correct response ($F=7.66$, $p=0.008$, $\eta p^2=0.119$) and the mean time taken to reach a correct response ($F=19.82$, $p<0.001$, $\eta p^2=0.258$), there was also a significant main effect of time. Tukey's multiple comparisons indicated that only the optimized multichannel tDCS group showed a significantly higher number of solved problems post-intervention compared to pre-intervention ($p=0.004$). No significant differences were found between the active and the sham

stimulation protocols in terms of committed errors and performance time, although the error

reduction was numerically greater after optimized multichannel tDCS (-35.3%) than the

conventional (-5.02%) and sham tDCS interventions (-6.73%) (Fig 5C).

3.5. Functional connectivity

Brain functional connectivity changes before and after the intervention were measured

with key connectivity measures related to cognitive impairment and emotional regulation such as

PLV, coherence, and global efficiency. Significant changes were only observed in the post-

intervention connectivity of the optimized multi-channel tDCS compared to the sham tDCS

(Figure 6). Specifically, theta, alpha, and beta PLV values significantly increased in the left

frontal-right temporal and left and right occipital regions following optimized multi-channel

tDCS compared to sham tDCS. For coherence, significant increases were observed in theta,

alpha, and beta coherence values after the optimized multi-channel tDCS across the left frontal

and right temporal regions, as well as for prefrontal-central coherence. Additionally, global

efficiency measured by wPLI showed a similar increase in connectivity within the prefrontal-

central region in the delta band and the Fronto-Parietal Network in the gamma band (see Figure 6

for details).

Fig. 6: **Functional connectivity**. Whole-brain functional connectivity after 30 sessions of optimized multichannel tDCS compared to sham tDCS. No significant differences were observed between conventional and sham tDCS post-intervention measurements. Red edges represent an increase in functional connectivity between respective nodes. Node colors represent specific regions- Frontal (Red), Central (Yellow), Parietal (Green), Occipital (Cyan), and Temporal (Dark Blue).

4. Discussion

In this randomized, sham-controlled clinical trial, we evaluated the efficacy of optimized

multichannel and conventional tDCS protocols compared to sham tDCS over the prefrontal

cortex on clinical symptoms, cognitive deficits, and cerebral functional connectivity in patients

with MD. Both optimized multichannel and conventional tDCS significantly alleviated depressive symptoms immediately after the intervention (session 30), and these improvements were sustained for up to three months post-intervention, outperforming the sham group. Therapeutic effects emerged as early as session 10 in the multichannel tDCS group, with the optimized multichannel protocol demonstrating a significantly greater effect size than conventional tDCS. Furthermore, the optimized multichannel tDCS group showed superior enhancement in cognitive performance, particularly in working memory and executive functions, compared to both conventional and sham tDCS. This protocol also led to increased cerebral functional connectivity, as evidenced by enhanced PLV, coherence, and global efficiency metrics, following the intervention. In contrast, no significant changes were observed in the sham group across outcome measures. This study is one of the largest tDCS trials conducted for depression treatment and is the first to utilize an optimized multi-channel tDCS protocol with a total stimulation intensity of 4 mA. In what follows we primarily discuss the clinical efficacy of the intervention, the study's primary objective, and the implications of cognitive and cerebral connectivity improvements for these findings.

4.1. Clinical efficacy

The study primarily aimed to assess the clinical efficacy of optimized multichannel tDCS and conventional tDCS versus sham tDCS. We found that optimized multichannel tDCS was clinically superior to both conventional and sham tDCS, although conventional tDCS also effectively reduced depressive symptoms compared to sham. Although the therapeutic effects of tDCS in depression, compared to other neuropsychiatric disorders, are well-supported in previous (Brunoni et al., 2017; Fregni et al., 2020) and recent well-conducted studies (Hausman

et al., 2024; Woodham et al., 2024), its clinical efficacy is not yet established and studies with negative and/or placebo effects (De Smet et al., 2021; Aust et al., 2022) have questioned tDCS efficacy. Comparing the clinical efficacy of this study to recent studies is, nevertheless, informative. One of the largest tDCS studies for depression treatment investigated the efficacy of conventional home-used tDCS (Woodham et al., 2024). In this study, which employed a conventional tDCS protocol similar to ours, the active tDCS group showed a significant improvement from baseline to week 10, with a mean reduction of 11.31 points on the MADRS compared to 7.74 points for sham treatment. In another study, remotely supervised multichannel tDCS was conducted at home in MD patients (N=35) (Ruffini et al., 2024b). The Ruffini et al. study reported a median MADRS score reduction of 19.8 points (64.5%; 48.6, 72.4) four weeks post-treatment, with Hedge's g = 3.10. In our study, we observed a response rate of 72.7% (n=24) with at least a 50% improvement in MADRS scores from baseline to the last visit four weeks post-treatment (Hedge's g = 2.80). Other clinical measures in our study indicated similar enhancements, with a reduction of about 12 points in the conventional group, 19 points in the multichannel active group, and 8 points in the sham group. Our results align well with studies using conventional and multichannel tDCS at home in terms of symptom reduction after conventional and multichannel tDCS. Additionally, they indicate that the optimized multichannel tDCS demonstrates greater clinical efficacy, achieving approximately a 19-point reduction in the MADRS compared to 13.5 points in conventional and 6.3 points in sham tDCS. The active protocols' overall efficacy aligns with recent meta-analyses indicating that a 2-mA stimulation current during a 30-minute tDCS session can enhance intervention effectiveness (Zhang et al., 2021). However, our study revealed significantly greater efficacy when this intervention is applied using an optimized multichannel configuration, which will be discussed further.

Furthermore, this finding can be partially explained from a neurophysiological perspective. The hallmark finding of neuroimaging studies refers to a lateral hypoconnectivity in the prefrontal cortex (especially in the left DLPFC) (Grimm et al., 2008a; Kaiser et al., 2015), which is the rationale for applying the most commonly used stimulation protocol in depression, excitatory left inhibitory right DLPFC stimulation (Nikolin et al., 2023). We applied anodal and cathodal stimulation over the left and right DLPFCs to un and downregulate the activity of these regions respectively. With causal modulation of cortical excitability with tDCS (Polanía et al., 2018), we expected to restore functional abnormalities in the MD-relevant brain circuitry, and this intervention was associated with behavioral and clinical improvement in this study. Moreover, clinical efficacy of the multichannel optimized stimulation was observed from the 10th session up to 3-month follow-up, which was not the case in the conventional tDCS and sham groups. The protocol used in the optimized multichannel group was designed by computational modeling (Ruffini et al., 2014) to deliver an En-field distribution that closely fits the target map, aiming to excite the left DLPFC and inhibit the right DLPFC. This optimization resulted in a significantly better fit of the multichannel En-field distribution to the target map, as reflected in the much higher NERNI (a normalized version of ERNI) value of 0.17 for the multichannel protocol compared to 0.018 for the bipolar protocol. This improved fit aligns with the larger effect size of clinical measures observed in the multichannel tDCS group and cognitive enhancement. Additionally, the optimized multichannel protocol allowed for higher total injected currents (4.0 mA, double that of the 2 mA bipolar protocol) which might partially explain larger clinical efficacy and cognitive outperformance in the optimized multichannel tDCS. In the template head model used for optimization, this resulted in an average En-field on target that was 1.3-1.4 times larger (for the left and right target areas, respectively) in the multichannel montage

compared to the bipolar montage. Both the fit to the target map and the E-field dose have been shown to correlate with quantitative measures of stimulation effects in other applications (Salvador et al., 2022; Junhong et al., 2025). Furthermore, other trials have demonstrated the effectiveness of using a modeling approach to optimize stimulation dose parameters in depression, even when employing variations of the target map used in this study (Ruffini et al., 2024b).

4.2. Cognitive performance and brain functional connectivity

The optimized multichannel tDCS significantly enhanced cognitive performance, specifically working memory and executive functions, in patients following the intervention, unlike conventional and sham tDCS. Notably, these cognitive deficits are key symptoms of MD, and their improvement, alongside clinical symptoms, indicates that the optimized tDCS intervention positively impacted both mood and cognitive deficits in MD, which are interconnected (Salehinejad et al., 2017; LeMoult and Gotlib, 2019). These cognitive deficits were repeatedly shown in MD (Kriesche et al., 2023) but results about cognitive effects of tDCS in depression and other disorders have been mixed or limited to memory functioning (Begemann et al., 2020; Wang et al., 2024a) and our study supports the cognitive potency of tDCS in MD (Begemann et al., 2020).

The changes in brain functional connectivity measures after the optimized multichannel vs sham tDCS protocol are in line with reduced biomarkers of depression symptoms. Previous EEG studies in depression have shown reduced synchronization (measured by PLV) across regions, specifically in the DMN, and prefrontal-limbic circuits (Liu et al., 2024; Wang et al., 2024b) which are linked to emotional dysregulation, and cognitive impairment in depression.

Similarly, lower coherence in frontotemporal regions and across theta, alpha, and beta bands has been observed in patients with depression. Our results indicate significant increases in PLV and coherence in these areas and frequency bands (see Figure 6), suggesting that targeted brain regions exhibit enhanced functional connectivity and synchronous cerebral oscillatory activity (e.g., theta and alpha bands) after the optimized multichannel tDCS intervention. These changes are associated with improved core cognitive functions (i.e., working memory and executive control) and regulated emotions (measured by clinical measures), which are usually seen in depression treatment response (Salehinejad et al., 2017; LeMoult and Gotlib, 2019; Brunoni et al., 2025).

4.3. Conclusion

Findings of this study show superior clinical efficacy and cognitive effects of the optimized multi-channel tDCS vs conventional and sham tDCS for treating depression. This study highlights the importance of optimizing stimulation parameters to effectively target specific cortical regions in the brain. Additionally, it suggests that optimized multichannel tDCS could be more effective in treating other neuropsychiatric disorders, and suggests the value of further research using computational modeling for precision stimulation (Ruffini et al., 2024a). The findings also underscore the significance of session frequency in assessing clinical efficacy, particularly in conventional tDCS protocols. Notably, the conventional tDCS significantly reduced depressive symptoms in two clinical outcome measures (HRDS and BDI-II) only after the 30th session. At the same time, the optimized multichannel tDCS showed reductions in depressive symptoms from the 10th session across all measures. This study had several limitations including the inability to assess cognitive functions and resting EEG during follow-up

due to COVID-19 and technical issues. Longer-term data could have provided deeper insights into tDCS effects on brain physiology and neuropsychological performance. We also did not evaluate blinding efficacy by asking patients about their intervention type. While stimulation intensity may lead to different skin sensations, reported tDCS side effects were similar across groups. Nonetheless, our findings support the effectiveness of the optimized multichannel tDCS for major depression and potentially other neuropsychiatric disorders, with improvements in treatment-related variables noted, especially in the optimized group, enhancing our understanding of treatment efficacy.

References

Alizadehgoradel J, Molaei B, Barzegar Jalali K, Pouresmali A, Sharifi K, Hallajian A-H, Nejati V, Glinski B, Vicario CM, Nitsche MA, Salehinejad MA (2024) Targeting the prefrontal-supplementary motor network in obsessive-compulsive disorder with intensified electrical stimulation in two dosages: a randomized, controlled trial. Translational Psychiatry 14:78.

Aust S, Brakemeier E-L, Spies J, Herrera-Melendez AL, Kaiser T, Fallgatter A, Plewnia C, Mayer SV, Dechantsreiter E, Burkhardt G, Strauß M, Mauche N, Normann C, Frase L, Deuschle M, Böhringer A, Padberg F, Bajbouj M (2022) Efficacy of Augmentation of Cognitive Behavioral Therapy With Transcranial Direct Current Stimulation for Depression: A Randomized Clinical Trial. JAMA Psychiatry 79:528-537.

Begemann MJ, Brand BA, Ćurčić-Blake B, Aleman A, Sommer IE (2020) Efficacy of non-invasive brain stimulation on cognitive functioning in brain disorders: a meta-analysis. Psychological Medicine:1-22.

Bikson M et al. (2016) Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimulation 9:641-661.

Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, Knyahnytska Y, Kennedy SH, Lam RW, Daskalakis ZJ (2018) Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. The Lancet 391:1683-1692.

Brunoni AR, Croarkin PE, Razza LB (2025) Emerging Trends in Non-Invasive Brain Stimulation: The New Kids on the Block. Biomedicines 13:14.

Brunoni AR, Schestatsky P, Lotufo PA, Benseñor IM, Fregni F (2014) Comparison of blinding effectiveness between sham tDCS and placebo sertraline in a 6-week major depression randomized clinical trial. Clin Neurophysiol 125:298-305.

Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F (2011) A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. International Journal of Neuropsychopharmacology 14:1133-1145.

Brunoni AR, Moffa AH, Sampaio-Junior B, Borrione L, Moreno ML, Fernandes RA, Veronezi BP, Nogueira BS, Aparicio LV, Razza LB (2017) Trial of electrical direct-current therapy versus escitalopram for depression. New England Journal of Medicine 376:2523-2533.

Cuijpers P et al. (2024) Absolute and relative outcomes of psychotherapies for eight mental disorders: a systematic review and meta-analysis. World Psychiatry 23:267-275.

De Smet S, Nikolin S, Moffa A, Suen P, Vanderhasselt M-A, Brunoni AR, Razza LB (2021) Determinants of sham response in tDCS depression trials: a systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry 109:110261.

Delorme A, Makeig S (2004) EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. J Neurosci Methods 134:9-21.

Ferrari AJ et al. (2024) Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet.

Fregni F, Pascual-Leone A (2007) Technology Insight: noninvasive brain stimulation in neurology[mdash]perspectives on the therapeutic potential of rTMS and tDCS. Nat Clin Pract Neuro 3:383-393.

Fregni F, El-Hagrassy MM, Pacheco-Barrios K, Carvalho S, Leite J, Simis M, Brunelin J, Nakamura-Palacios EM, Marangolo P, Venkatasubramanian G, San-Juan D, Caumo W, Bikson M, Brunoni AR, Group NCW (2020) Evidence-Based Guidelines and Secondary Meta-Analysis for the Use of Transcranial

Direct Current Stimulation in Neurological and Psychiatric Disorders. International Journal of Neuropsychopharmacology 24:256-313.

Galan-Gadea A, Salvador R, Bartolomei F, Wendling F, Ruffini G (2023) Spherical harmonics representation of the steady-state membrane potential shift induced by tDCS in realistic neuron models. Journal of Neural Engineering 20:026004.

Gandiga PC, Hummel FC, Cohen LG (2006) Transcranial DC stimulation (tDCS): A tool for double-blind sham-controlled clinical studies in brain stimulation. Clinical Neurophysiology 117:845-850.

Gautam S, Jain A, Gautam M, Vahia VN, Grover S (2017) Clinical Practice Guidelines for the management of Depression. Indian J Psychiatry 59:S34-s50.

Grimm S, Beck J, Schuepbach D, Hell D, Boesiger P, Bermpohl F, Niehaus L, Boeker H, Northoff G (2008a) Imbalance between Left and Right Dorsolateral Prefrontal Cortex in Major Depression Is Linked to Negative Emotional Judgment: An fMRI Study in Severe Major Depressive Disorder. Biological Psychiatry 63:369-376.

Grimm S, Boesiger P, Beck J, Schuepbach D, Bermpohl F, Walter M, Ernst J, Hell D, Boeker H, Northoff G (2008b) Altered Negative BOLD Responses in the Default-Mode Network during Emotion Processing in Depressed Subjects. Neuropsychopharmacology 34:932-843.

Guilbert JJ (2003) The world health report 2002 - reducing risks, promoting healthy life. Educ Health (Abingdon) 16:230.

Hausman HK, Alexander GE, Cohen R, Marsiske M, DeKosky ST, Hishaw GA, O'Shea A, Kraft JN, Dai Y, Wu S, Woods AJ (2024) tDCS reduces depression and state anxiety symptoms in older adults from the augmenting cognitive training in older adults study (ACT). Brain Stimulation 17:283-311.

Huang MH, Fan SY, Lin IM (2023) EEG coherences of the fronto-limbic circuit between patients with major depressive disorder and healthy controls. J Affect Disord 331:112-120.

Junhong Z, Salvador R, LaGanke N, Yu W, Ruffini G, Pascual-Leone A, Manor B (2025) optimization of the "dose-response" relationship of transcranial direct current stimulation. Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation.

Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA (2015) Large-Scale Network Dysfunction in Major Depressive Disorder: A Meta-analysis of Resting-State Functional Connectivity. JAMA Psychiatry 72:603-611.

Kendrick T, Taylor D, Johnson CF (2019) Which first-line antidepressant? Br J Gen Pract 69:114-115.

Kriesche D, Woll CFJ, Tschentscher N, Engel RR, Karch S (2023) Neurocognitive deficits in depression: a systematic review of cognitive impairment in the acute and remitted state. European Archives of Psychiatry and Clinical Neuroscience 273:1105-1128.

Kühner C, Bürger C, Keller F, Hautzinger M (2007) Reliability and validity of the Revised Beck Depression Inventory (BDI-II) results from German samples. Der Nervenarzt 78:651-656.

Lachaux J-P, Rodriguez E, Martinerie J, Varela FJ (1999) Measuring phase synchrony in brain signals. Hum Brain Mapp 8:194-208.

Langley C, Sahakian BJ, Robbins TW (2023) Cambridge Neuropsychological Test Automated Battery (CANTAB). The SAGE Handbook of Clinical Neuropsychology: Clinical Neuropsychological Assessment and Diagnosis:435.

LeMoult J, Gotlib IH (2019) Depression: A cognitive perspective. Clinical Psychology Review 69:51-66.

Liu X, Zhang H, Cui Y, Zhao T, Wang B, Xie X, Liang S, Sha S, Yan Y, Zhao X, Zhang L (2024) EEG-based major depressive disorder recognition by neural oscillation and asymmetry. Frontiers in Neuroscience 18.

Miranda PC, Mekonnen A, Salvador R, Ruffini G (2013) The electric field in the cortex during transcranial current stimulation. Neuroimage 70:48-58.

Moffa AH, Martin D, Alonzo A, Bennabi D, Blumberger DM, Benseñor IM, Daskalakis Z, Fregni F, Haffen E, Lisanby SH, Padberg F, Palm U, Razza LB, Sampaio-Jr B, Loo C, Brunoni AR (2020) Efficacy and

acceptability of transcranial direct current stimulation (tDCS) for major depressive disorder: An individual patient data meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry 99:109836.

Montgomery SA, Åsberg M (1979) A New Depression Scale Designed to be Sensitive to Change. Br J Psychiatry 134:382-389.

Mulders PC, van Eijndhoven PF, Schene AH, Beckmann CF, Tendolkar I (2015) Resting-state functional connectivity in major depressive disorder: A review. Neuroscience & Biobehavioral Reviews 56:330-344.

Mutz J, Vipulananthan V, Carter B, Hurlemann R, Fu CHY, Young AH (2019) Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ 364:l1079.

Nikolin S, Moffa A, Razza L, Martin D, Brunoni A, Palm U, Padberg F, Bennabi D, Haffen E, Blumberger DM, Salehinejad MA, Loo CK (2023) Time-course of the tDCS antidepressant effect: An individual participant data meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry 125:110752.

Nitsche M, Paulus W (2000) Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. The Journal of Physiology 527:633-639.

Nunez PL, Srinivasan R, Westdorp AF, Wijesinghe RS, Tucker DM, Silberstein RB, Cadusch PJ (1997) EEG coherency. I: Statistics, reference electrode, volume conduction, Laplacians, cortical imaging, and interpretation at multiple scales. Electroencephalogr Clin Neurophysiol 103:499-515.

Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, Mohr DC, Schatzberg AF (2016) Major depressive disorder. Nature Reviews Disease Primers 2:16065.

Polania R, Kuo M-F, Nitsche MA (2021) Physiology of Transcranial Direct and Alternating Current Stimulation. In: Transcranial Direct Current Stimulation in Neuropsychiatric Disorders: Clinical Principles and Management (Brunoni AR, Nitsche MA, Loo CK, eds), pp 29-47. Cham: Springer International Publishing.

Polanía R, Nitsche MA, Ruff CC (2018) Studying and modifying brain function with non-invasive brain stimulation. Nat Neurosci 21:174-187.

Razza LB, Palumbo P, Moffa AH, Carvalho AF, Solmi M, Loo CK, Brunoni AR (2020) A systematic review and meta-analysis on the effects of transcranial direct current stimulation in depressive episodes. Depression and Anxiety 37:594-608.

Reynolds WM, Kobak KA (1995) Reliability and validity of the Hamilton Depression Inventory: A paper-and-pencil version of the Hamilton Depression Rating Scale Clinical Interview. Psychol Assess 7:472.

Rimmer RM, Costafreda SG, Mutz J, Joseph K, Brunoni AR, Loo CK, Padberg F, Palm U, Fu CHY (2022) Transcranial direct current stimulation effects in late life depression: A meta-analysis of individual participant data. Journal of Affective Disorders Reports 10:100407.

Ruffini G, Fox MD, Ripolles O, Miranda PC, Pascual-Leone A (2014) Optimization of multifocal transcranial current stimulation for weighted cortical pattern targeting from realistic modeling of electric fields. Neuroimage 89:216-225.

Ruffini G, Castaldo F, Lopez-Sola E, Sanchez-Todo R, Vohryzek J (2024a) The Algorithmic Agent Perspective and Computational Neuropsychiatry: From Etiology to Advanced Therapy in Major Depressive Disorder. Entropy 26:953.

Ruffini G, Salvador R, Castaldo F, Baleeiro T, Camprodon JA, Chopra M, Cappon D, Pascual-Leone A (2024b) Multichannel tDCS with advanced targeting for major depressive disorder: a tele-supervised at-home pilot study. Frontiers in Psychiatry 15.

Sahakian BJ, Owen AM (1992) Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J R Soc Med 85:399-402.

Salehinejad MA, Siniatchkin M (2024) Safety of noninvasive brain stimulation in children. Current Opinion in Psychiatry:10.1097/YCO.0000000000000923.

Salehinejad MA, Ghanavai E, Rostami R, Nejati V (2017) Cognitive control dysfunction in emotion dysregulation and psychopathology of major depression (MD): Evidence from transcranial brain stimulation of the dorsolateral prefrontal cortex (DLPFC). Journal of Affective Disorders 210:241-248.

Salehinejad MA, Ghanavati E, Glinski B, Hallajian A-H, Azarkolah A (2022a) A systematic review of randomized controlled trials on efficacy and safety of transcranial direct current stimulation in major neurodevelopmental disorders: ADHD, autism, and dyslexia. Brain and Behavior 12:e2724.

Salehinejad MA, Wischnewski M, Ghanavati E, Mosayebi-Samani M, Kuo M-F, Nitsche MA (2021) Cognitive functions and underlying parameters of human brain physiology are associated with chronotype. Nature Communications 12:4672.

Salehinejad MA, Ghanavati E, Reinders J, Hengstler JG, Kuo M-F, Nitsche MA (2022b) Sleep-dependent upscaled excitability, saturated neuroplasticity, and modulated cognition in the human brain. eLife 11:e69308.

Salvador R, Biagi MC, Pelegrí MP, Zhou J, Travison T, Pascual-Leone A, Manor B, Ruffini G (2022) Towards the identification and optimization of the "dose-response" relationship of transcranial direct current stimulation. bioRxiv:2022.2001.2022.477353.

Stagg CJ, Nitsche MA (2011) Physiological Basis of Transcranial Direct Current Stimulation. The Neuroscientist 17:37-53.

Stagg CJ, Antal A, Nitsche MA (2018) Physiology of Transcranial Direct Current Stimulation. The Journal of ECT 34:144-152.

Sweeney JA, Kmiec JA, Kupfer DJ (2000) Neuropsychologic impairments in bipolar and unipolar mood disorders on the CANTAB neurocognitive battery. Biological Psychiatry 48:674-684.

Tadel F, Baillet S, Mosher JC, Pantazis D, Leahy RM (2011) Brainstorm: a user-friendly application for MEG/EEG analysis. Comput Intell Neurosci 2011:1-13.

Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z (2006) Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 63:1217-1223.

Vinck M, Oostenveld R, van Wingerden M, Battaglia F, Pennartz CM (2011) An improved index of phase-synchronization for electrophysiological data in the presence of volume-conduction, noise and sample-size bias. Neuroimage 55:1548-1565.

Wang J, Yao X, Ji Y, Li H (2024a) Cognitive potency and safety of tDCS treatment for major depressive disorder: a systematic review and meta-analysis. Frontiers in Human Neuroscience 18.

Wang Y, Chen X, Liu R, Zhang Z, Zhou J, Feng Y, Zeidman P, Wang G, Zhou Y (2022) Disrupted effective connectivity of the default, salience and dorsal attention networks in major depressive disorder: a study using spectral dynamic causal modelling of resting-state fMRI. J Psychiatry Neurosci 47:E421-E434.

Wang Y, Chen Y, Cui Y, Zhao T, Wang B, Zheng Y, Ren Y, Sha S, Yan Y, Zhao X, Zhang L, Wang G (2024b) Alterations in electroencephalographic functional connectivity in individuals with major depressive disorder: a resting-state electroencephalogram study. Frontiers in Neuroscience 18.

Woodham RD, Selvaraj S, Lajmi N, Hobday H, Sheehan G, Ghazi-Noori A-R, Lagerberg PJ, Rizvi M, Kwon SS, Orhii P, Maislin D, Hernandez L, Machado-Vieira R, Soares JC, Young AH, Fu CHY (2024) Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote phase 2 randomized sham-controlled trial. Nat Med.

Zhang R, Lam CLM, Peng X, Zhang D, Zhang C, Huang R, Lee TMC (2021) Efficacy and acceptability of transcranial direct current stimulation for treating depression: A meta-analysis of randomized controlled trials. Neuroscience & Biobehavioral Reviews 126:481-490.

Acknowledgments

MAN is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—Project Number 316803389—SFB 1280, project A6, and by the German Centre of Mental Health (Project Number 01EE2302D). We would like to thank Dr. Ali Fathi Jouzdani, Prof. Reza Rostami, Dr. Ahmad Zolghadrihafor, Miss Vida Yousefi Asl, Dr. Soroush Lohrasbi, Dr. Alireza Moradi and Mr Yashar Abolfathi for their technical support during data acquisition and manuscript preparation.

Conflict of Interest Disclosures

MAN is a member of the Scientific Advisory Boards of Neuroelectrics and NeuroDevice. All other authors declare no competing interests. Giulio Ruffini and Ricardo Salvador work for Neuroelectrics. Giulio Ruffini is a co-founder of Neuroelectrics.

Author Contributions

Mohammad Ali Salehinejad: Conceptualization, Methodology, Supervision, Writing – original draft, Writing - review & editing, Formal analysis (Clinical and behavioral data). **Marzieh Abdi**: Investigation, Data curation, Validation. **Mohsen Dadashi:** Resources, Project administration, Data curation, Validation. **Amir-Homayun Hallajian** & **Kiomars Sharifi**: Formal analysis (EEG). **Ali Khadem**: Resources. **Ricardo Salvador** & **Giulio Ruffini**: Resources, modeling, visualization. **Michael A. Nitsche**: Supervision, Methodology, Writing - review & editing. Marzieh Abdi had full access to data an takes responsibility for the integrity and accuracy of data.

Tables

Table 1. Demographic data

		Optimized multichannel tDCS	conventional tDCS	sham tDCS	*p* *
Sample size (*n*)		20	20	20	
Age – Mean (SD)		32.15 (12.18)	35.75 (11.38)	29.60 (8.06)	0.197
Sex – Male (female)		11 (9)	11 (9)	5 (15)	0.089
Job	student	7	14	10	0.241
	self-employed	5	5	3	
	housewife/husband	3	7	1	
	employee	4	3	6	
	unemployed	1	1	0	
Education	Below diploma	1	5	0	0.047
	Diploma	10	7	4	
	Bachelors degree	6	4	11	
	Masters degree	1	2	5	
	PhD level	2	2	0	
Marital status	single	9	11	12	0.457
	married	10	9	7	
	divorced	1	0	1	
On medication (n)		17	18	15	0.368
Type of medication	SSRI	14	16	13	
	Tricyclic	3	2	2	
	Other	0	0	0	

Note: tDCS = transcranial Direct Current Stimulation; M = Mean; SD = Standard Deviation. * = between-group differences in demographic variables were explored by Chi-square tests or Fisher's exact test for categorical variables and *F* tests for continuous variables.

Figure Legends

Fig. 1: CONSORT diagram of study inclusion.

Fig. 2: Distribution of the normal component of the E-field (En, in V/m) in a surface inside the grey matter tissue, in between the grey matter-CSF and white matter-grey matter interfaces. Panel a shows the En-distribution for a conventional protocol using a bipolar electrode montage with rectangular 7x5 cm2 sponge electrodes (anode/cathode over F3/F4) at +2/-2-mA. Panel b illustrates the En-distribution for a multichannel optimized protocol using gelled electrodes (1 cm radius PiStim electrodes, anodes shown in red, cathodes in blue) targeting Brodmann area 46, presumed to result in excitability enhancement in the left hemisphere and excitability reduction in the right. Positive En values indicate that the En-field is directed into the cortical surface, thus leading to an increase in cortical excitability, according to the lambda-E model. Negative En values are directed in the opposite direction, thus leading to a decrease of excitability.

Fig. 3: Study procedure. The experiment was conducted in a randomized, double-blind, sham-controlled parallel-group design. Patients were assigned to one of three tDCS groups: 2-mA conventional tDCS [total injected current 2 mA] (n = 20), 2-mA optimized multichannel tDCS [total injected current 4 mA] (n = 20), and sham tDCS (n = 20). All participants underwent 30 daily stimulation sessions. Depressive symptoms were evaluated before the intervention and up to three months afterward. Cognitive performance and cerebral functional connectivity were assessed only before and after the intervention due to the COVID-19 pandemic.

Fig. 4: Depressive symptoms measured by the Hamilton Depression Rating Scale (HDRS) (A), Montgomery–Åsberg Depression Rating Scale (MADRS) (B), and Beck Depression Inventory (BDI-II) (C) before, after, and up to 3 months following up the intervention/ In the left panel, filled symbols indicate significant differences at each time point compared to pre-intervention scores. The red and blue floating symbols represent significant differences between the active stimulation groups (conventional and multichannel tDCS) and sham tDCS at each time point. Asterisks show the difference between the multichannel vs sham tDCS groups at respective time points. The right panel displays a scatter plot of clinical scores for each group across time points. All pairwise comparisons used Tukey's multiple-test method, and error bars indicate the standard error of the mean (s.e.m.). Note: HDRS = Hamilton Depression Rating Scale; MADRS = Montgomery–Åsberg Depression Rating Scale; BDI-II = Beck Depression Inventory-II; tDCS = transcranial direct current stimulation; mo = month.

Fig. 5: Cognitive performance was evaluated before and after 30 sessions of optimized multichannel, conventional, and sham tDCS using the CANTAB neuropsychological test battery for depression, which includes measures of working memory (SWM) (A), sustained attention (RVP) (B), and executive functioning (OTS) (C). Asterisks indicate significant differences for pre- and post-intervention comparisons while floating symbols, depending on the color, denote significant group differences (in this case multichannel tDCS vs sham or conventional tDCS) at each time point. Tukey's multiple-test method was used for all pairwise comparisons, and error bars indicate the standard error of the mean (s.e.m.). Note: SWM = Spatial Working Memory;

RVP = Rapid Visual Processing; OTS = One Touch Stocking of Cambridge; tDCS = transcranial direct current stimulation.

Fig. 6: Whole-brain functional connectivity after 30 sessions of optimized multichannel tDCS compared to sham tDCS. No significant differences were observed between conventional and sham tDCS post-intervention measurements. Red edges represent an increase in functional connectivity between respective nodes. Node colors represent specific regions- Frontal (Red), Central (Yellow), Parietal (Green), Occipital (Cyan), and Temporal (Dark Blue).